Pierre Fabre Obtains European Commission Marketing Authorization For Hemangiol®, The First And Only Drug Approved For The Treatment Of Proliferating Infantile Hemangioma
5/5/2014 9:05:15 AM
CASTRES, France--(BUSINESS WIRE)--Pierre Fabre Dermatologie Laboratories have obtained European Commission authorization to market Hemangiol® (propranolol), the first and only drug to be approved for the treatment of “proliferating infantile hemangioma requiring systemic treatment”. Hemangiol® is an oral solution specially developed for pediatric use. It will be launched firstly in France and Germany, and gradually throughout other European markets.
Help employers find you! Check out all the jobs and post your resume.
comments powered by